Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 941-453-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
For L-threonine mother liquor itself there are no studies available. Therefore, data for the read-across substance Biofert Plusz are taken into further consideration.
In a sub-acute gavage range-finding study in male and female Wistar rats oral application of up to 1000 mg/kg bw/day (related to dry mass) for 14 days did not result in clinical signs, effects on body weight or food consumption, in relevant macroscopical changes at necropsy or effects on organ weights.
In a sub-chronic 90 d gavage GLP study according to OECD Guideline 408 with male and female Wistar rats, no effects of toxicological relevance were detected even at the high dose level of 1000 mg/kg bw/day (related to dry mass).
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- In accordance with Section 8.6.2 in column 1&2 of REACH Annex VIII testing of sub-chronic toxicity via the inhalation route is not required. The read-across substance Biofert Plusz has very low vapour pressure (< 3*10E-5 hPa at 20°C) and based on the composition of Biofert Plusz, this vapour pressure applies likewise to L-threonine mother liquor. Therefore, the potential for the generation of inhalable forms is low and also the use of this substance will not result in aerosols, particles or droplets of an inhalable size, so that exposure to humans via the inhalation route is unlikely to occur. Furthermore the results of laboratory animal studies performed with Biofert Plusz show low acute dermal toxicity. In a 90 d oral repeated dose toxicity study with Biofert Plusz, the administration of up to 1000 mg/kg bw/d (related to dry mass) does not exacerbate systemic toxicity effects. The highest dose level tested corresponds to the limit dose recommended by the respective OECD guideline and is indicating both a low bioavailability and a low toxicity potential. This intrinsic property/toxicity potential can be extrapolated to repeated inhalation route administration.
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- In accordance with Section 8.6.2 in column 1&2 of REACH Annex VIII testing of sub-chronic toxicity via the dermal route is not required. The toxicological properties of L-threonine mother liquor and the read-across substance Biofert Plusz are indicating a low potential for a significant absorption via the oral and dermal route. In addition, in a 90 d oral repeated dose toxicity study with Biofert Plusz, the administration of up to 1000 mg/kg bw/d (related to dry mass) does not exacerbate systemic toxicity effects. The highest dose level tested corresponds to the limit dose recommended by the respective OECD guideline and is indicating both a low bioavailability and a low toxicity potential. This intrinsic property/toxicity potential can be extrapolated to repeated dermal route administration.
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
In a 14 day gavage range-finding study with Biofert Plusz, dose levels of 100 - 1000 mg/kg bw/d (related to dry mass) were administered once daily to Wistar rats of both sexes (n=5 per sex and dose). Parameters investigated were clinical signs, body weights and food consumption, organ weights and macroscopic findings. None of these parameters was changed by the test item at any of the dose levels tested.
In a subsequent 90 d gavage GLP study according to OECD Guideline 408 with Biofert Plusz, male and female Wistar rats (n=10 per dose and sex) were dosed daily with the undiluted test substance at dose levels of 100 - 1000 mg/kg bw/d. The treatment caused no adverse effects at any of the applied doses.
In both studies the highest dose level tested corresponds to the limit dose recommended by the respective OECD guideline.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.